Prestige Consumer Healthcare Inc. $PBH Stock Holdings Reduced by Carnegie Lake Advisors LLC

Carnegie Lake Advisors LLC reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 93.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,058 shares of the company’s stock after selling 15,736 shares during the quarter. Carnegie Lake Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $49,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $370,187,000. Dimensional Fund Advisors LP grew its stake in shares of Prestige Consumer Healthcare by 3.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock valued at $158,414,000 after buying an additional 91,710 shares during the period. Rice Hall James & Associates LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $32,602,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $31,135,000. Finally, Bank of America Corp DE bought a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at about $26,277,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. Canaccord Genuity Group reduced their price objective on Prestige Consumer Healthcare from $72.00 to $70.00 and set a “buy” rating for the company in a research note on Friday. Finally, Zacks Research downgraded Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 29th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $67.00.

More Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Fiscal Q2 adjusted earnings were $1.13 per share, topping the $1.07 consensus, while revenue of $336.31 million exceeded estimates of about $329 million and rose 22.7% year over year. Prestige Consumer Healthcare fiscal 2027 second-quarter results
• Neutral Sentiment: Canaccord Genuity lowered its price target from $72 to $70 but maintained a Buy rating. The reduced target is a mild negative, though it still implies substantial upside from the cited share price. Canaccord Genuity Group stock recommendations
• Negative Sentiment: A recent report highlights PBH’s stock drop, but the provided article details do not specify what is driving the decline. The weakness despite an earnings and revenue beat may indicate investors are weighing concerns not explained in the available coverage. Prestige Consumer Healthcare stock dropped: what is driving attention now?

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $43.03 on Monday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $41.77 and a fifty-two week high of $71.07. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of 13.28, a PEG ratio of 1.35 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.86 and a current ratio of 2.92. The firm’s 50-day simple moving average is $48.17 and its 200 day simple moving average is $53.77.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.06. The business had revenue of $336.31 million during the quarter, compared to the consensus estimate of $329.14 million. Prestige Consumer Healthcare had a return on equity of 11.28% and a net margin of 13.29%. The company’s quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.07 EPS. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.55 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.